Can event-related oscillations aid in differentiating Parkinson’s disease and dementia with Lewy bodies?
Objective: To assess the specificity of an EEG signature of the visual event-related oscillations (ERO) in synucleinopathies. Background: Parkinson's disease (PD), PD dementia (PDD) and…Neuroleptic Malignant Syndrome: Case Series of Movement Disorders Emergency
Objective: We describe four cases of Neuroleptic Malignant Syndrome (NMS) with high mortality rates, despite decreased reports of the disease in the past decades. Background:…EFFECT OF TRANSCRANIAL DIRECT CURRENT STIMULATION (tDCS) ON LOCOMOTOR FUNCTION IN PATIENTS WITH PARKINSON’S DISEASE
Objective: Objectives Primary objective: To determine the effect of bilateral anodal transcranial direct current stimulation (tDCS) on locomotor function in patients with Parkinson’s disease immediately…Disparities in Access to Spasticity Chemodenervation Specialists in the United States: a National Analysis of Medicare Data
Objective: To explore the variations in access to spasticity chemodenervation specialists across several geographical, ethnic, racial, and population density factors. Background: Equity in access to…Modeling of the Placebo Response in Parkinson’s Disease
Objective: The objective of this study was to investigate the predictability of the placebo response in Parkinson's disease (PD) subjects participating in a randomized clinical…Relationship of satisfaction and adherence in remote digital monitoring: Results from a clinical drug trial in early Parkinson’s disease
Objective: To investigate satisfaction with daily remote monitoring with a digital health technology tool (DHTT) in individuals with early Parkinson’s disease (PD) and the relationship…LRRK2 Inhibition by BIIB122 / DNL151: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Ph 1 Healthy Volunteer and Ph 1B Parkinson’s Disease Trials
Objective: To evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of the LRRK2 inhibitor, DNL151 (BIIB122), in healthy volunteers (HVs) and Parkinson’s disease (PD) patients. Background:…A new fully implantable Adaptive Deep Brain Stimulation system tested for the first time in patients with Parkinson’s Disease
Objective: This multicenter double-blind crossover study has been designed to evaluate the safety and efficacy of adaptive Deep Brain Stimulation delivered through an innovative IPG…Subcutaneous Levodopa Infusion for Parkinson’s disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study
Objective: To review one-year exploratory efficacy data from the ND0612 BeyoND study. Background: ND0612 is an investigational subcutaneous delivery system providing minimally invasive, continuous infusion…Long-Term Evaluation of Deep Brain Stimulation for Treatment of Parkinson’s Disease Using a Multiple-Source, Constant-Current Rechargeable System: 4-year Follow-Up of a Prospective, Double-Blind RCT
Objective: The long-term effectiveness of a Deep Brain Stimulation (DBS) device capable of Multiple Independent Current Control (MICC) is assessed in a prospective, sham-controlled, double-blind…
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 132
- Next Page »